Search

Your search keyword '"Jeon, Dabee"' showing total 5 results
Start Over Author "Jeon, Dabee"
5 results on '"Jeon, Dabee"'

1. Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study

Author

Papp, Kim A., Lebwohl, Mark G., Thaçi, Diamant, Jaworski, Janusz, Kwiek, Bartlomiej, Trefler, Jakub, Dudek, Anna, Szepietowski, Jacek C., Reznichenko, Nataliya, Narbutt, Joanna, Baran, Wojciech, Kolinek, Joanna, Daniluk, Stefan, Bartnicka-Maslowska, Katarzyna, Reich, Adam, Andrashko, Yuriy, Kim, Sunghyun, Bae, Yunju, Jeon, Dabee, Jung, Jinsun, Lee, Hyunseung, Pyo, Tina, and Ko, Woori

Published
2024
Full Text
View/download PDF

2. Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study

Author

Yu, Kyung-Sang, Ryu, Hyunwook, Shin, Dongseong, Park, MinKyu, Hwang, JunGi, Moon, Seol Ju, Kim, Min-Gul, Keystone, Edward, Smolen, Josef S, Kim, SungHyun, Bae, YunJu, Jeon, DaBee, Jang, JiYoung, Yang, GoEun, Bae, JiHun, Lee, JaeYong, and Burmester, Gerd R

Abstract

ABSTRACTBackgroundThis study compared the pharmacokinetics (PK), immunogenicity, and safety of candidate tocilizumab biosimilar, CT-P47, administered via auto-injector (CT-P47 AI) or pre-filled syringe (CT-P47 PFS), in healthy Asian adults.Research design and methodsIn this phase I, multicenter, open-label study, participants were randomized 1:1 to receive a single 162 mg/0.9 mL dose of CT-P47 via AI or PFS. Primary endpoints were area under the concentration – time curve from time zero to infinity (AUC0–inf) and maximum serum concentration (Cmax). PK equivalence was determined if 90% confidence intervals (CIs) for the ratios of geometric least-squares means (gLSMs) were within the predefined 80–125% equivalence margin. Secondary PK parameters, immunogenicity, and safety outcomes were also assessed.ResultsOf 314 participants randomized (155 CT-P47 AI; 159 CT-P47 PFS), 310 received the study drug (153 CT-P47 AI; 157 CT-P47 PFS). Primary and secondary PK results, immunogenicity and safety were similar between groups. Ninety percent CIs for the ratio of gLSMs were within the predefined equivalence margin for AUC0–inf(85.87–102.94) and Cmax(82.98–98.16).ConclusionsPK equivalence between CT-P47 AI and CT-P47 PFS was demonstrated in healthy Asian adults, with comparable immunogenicity and safety between the two devices.Trial registrationClinicalTrials.gov: NCT05617183.

Published
2024
Full Text
View/download PDF

3. Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study

Author

Papp, Kim A., primary, Lebwohl, Mark G., additional, Thaçi, Diamant, additional, Jaworski, Janusz, additional, Kwiek, Bartlomiej, additional, Trefler, Jakub, additional, Dudek, Anna, additional, Szepietowski, Jacek C., additional, Reznichenko, Nataliya, additional, Narbutt, Joanna, additional, Baran, Wojciech, additional, Kolinek, Joanna, additional, Daniluk, Stefan, additional, Bartnicka-Maslowska, Katarzyna, additional, Reich, Adam, additional, Andrashko, Yuriy, additional, Kim, Sunghyun, additional, Bae, Yunju, additional, Jeon, Dabee, additional, Jung, Jinsun, additional, Lee, Hyunseung, additional, Pyo, Tina, additional, and Ko, Woori, additional

Published
2023
Full Text
View/download PDF

4. Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study

Author

Yu, Kyung-Sang, primary, Kim, Byungwook, additional, Shin, Dongseong, additional, Park, Min Kyu, additional, Hwang, Jun Gi, additional, Kim, Min-Gul, additional, Chung, Hyewon, additional, Ghim, JongLyul, additional, Chung, Jae-Yong, additional, Smolen, Josef S., additional, Burmester, Gerd R., additional, Kim, SungHyun, additional, Bae, YunJu, additional, Jeon, DaBee, additional, Yoo, JaeKyoung, additional, Yang, GoEun, additional, Bae, JiHun, additional, and Keystone, Edward, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results